|

Strength Training Response of Muscle in GLP-1 Users

RECRUITINGN/ASponsored by Virginia Polytechnic Institute and State University
Actively Recruiting
PhaseN/A
SponsorVirginia Polytechnic Institute and State University
Started2025-10-08
Est. completion2026-12
Eligibility
Age50 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT07104539

Summary

GLP-1 medication is being prescribed for weight loss. However, GLP-1 medication may adversely affect muscle mass and muscle function. Moreover, any loss of muscle mass or muscle function with GLP-1 treatment may impair balance and increase fall risk. This is a particular concern among older adults already susceptible to the common muscle strength and muscle function loss with age, yet there is little evidence among this population. This study will address a gap in knowledge regarding the effects of GLP-1 treatment on muscle mass, muscle function, and balance/fall risk among adults age 50 and older.

Eligibility

Age: 50 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age, 50y+
* Be taking GLP-1 medicine (Weygovy or Zepbound) for 1 month or less
* Weight \<300 lb
* Pass a health and exercise readiness screening

Exclusion Criteria:

* Age \<50
* Weight \>300 lb
* Osteoporosis
* Active metabolic, neoplastic, or cardiovascular disease
* Unable or unwilling to provide consent

Conditions2

Muscle MassWeight Loss

Locations1 site

Virginia Tech
Blacksburg, Virginia, 24061

Browse More Trials

Weight Loss trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.